BioCentury
ARTICLE | Clinical News

Atazanavir: Phase III data

August 11, 2008 7:00 AM UTC

In the open-label, international Phase III CASTLE study in 883 antiretroviral-naïve patients with HIV-1, once-daily atazanavir/ritonavir was non-inferior to twice-daily Kaletra lopinavir/ritonavir on...